Lanreotide

What is Lanreotide?

Lanreotide (brand name SOMATULINE DEPOT in the US, SOMATULINE AUTOGEL in Europe; development code BIM 23014) is a synthetic cyclic octapeptide somatostatin analogue that selectively binds and activates somatostatin receptors SSTR2 and SSTR5. It is the principal alternative to octreotide LAR for chronic somatostatin therapy.

It was approved by the FDA on August 30, 2007 for acromegaly and on December 16, 2014 for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Lanreotide is administered as a deep subcutaneous injection once every 4 weeks via a prefilled syringe — a more convenient profile than octreotide LAR's deep intramuscular injection.

Structure and Mechanism

Lanreotide shares the same SSTR2/5-selective binding profile as octreotide, with very similar clinical pharmacology. The two drugs are largely interchangeable in clinical practice.

• SSTR2 activation — suppresses growth hormone (acromegaly), tumor proliferation in NETs, and gastrointestinal hormone secretion (carcinoid syndrome)
• SSTR5 activation — suppresses insulin and contributes to GH suppression
• Negligible SSTR1/3/4 activity — distinguishes lanreotide and octreotide from pasireotide

Lanreotide differs structurally from octreotide and offers a different pharmaceutical formulation (saturated peptide depot suspension vs microsphere depot for octreotide LAR), but receptor pharmacology is essentially equivalent.

Clinical Evidence

CLARINET Phase 3 trial in NETs (NEJM 2014):

• 204 patients with non-functioning GEP-NETs (G1/G2, predominantly grade 1)
• Randomized to lanreotide depot 120 mg every 4 weeks vs placebo
• Median PFS not reached vs 18.0 months placebo (HR 0.47, 53% reduction in progression risk)
• Established lanreotide as first-line antiproliferative therapy in well-differentiated GEP-NETs

Acromegaly trials (multiple):

• Long-term efficacy in normalizing GH and IGF-1 in 60-70% of acromegaly patients
• Comparable to octreotide LAR in head-to-head studies

Approval History

• August 30, 2007 — FDA approval for acromegaly
• December 16, 2014 — FDA approval for GEP-NETs (G1, G2 advanced)
• 2017 — FDA expanded GEP-NET indication to carcinoid syndrome
• EMA approved — earlier in EU (Somatuline Autogel, 2002)

Place in Therapy

In acromegaly: lanreotide is one of two first-line medical therapies (with octreotide LAR), used after pituitary surgery in patients with persistent disease, or as primary therapy in non-surgical candidates.

In GEP-NETs: lanreotide is first-line antiproliferative therapy for well-differentiated tumors, often combined with hepatic-directed therapies or 177Lu-DOTATATE in advanced cases.

In carcinoid syndrome: controls flushing and diarrhea via 5-HIAA suppression.

Safety Profile

Adverse events parallel octreotide:

• Cholelithiasis and gallbladder sludge (~25% over years of use)
• Diarrhea and abdominal cramping
• Hyperglycemia (typically mild)
• Bradycardia
• Injection-site reactions

Distinction from Octreotide and Pasireotide